Holen Sie sich die Stockscreener-App
63.25
2.02%
1.25
Handel nachbörslich:
63.25
Schlusskurs vom Vortag:
$62.00
Offen:
$62.5
24-Stunden-Volumen:
709.70K
Relative Volume:
1.05
Marktkapitalisierung:
$1.60B
Einnahmen:
$56.54M
Nettoeinkommen (Verlust:
$-30.70M
KGV:
-162.18
EPS:
-0.39
Netto-Cashflow:
$-31.05M
1W Leistung:
+2.03%
1M Leistung:
+25.16%
6M Leistung:
+171.11%
1J Leistung:
+420.58%
1-Tages-Spanne:
$60.30
$63.27
1-Wochen-Bereich:
$56.53
$64.26
52-Wochen-Spanne:
$10.14
$66.94
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Firmenname
Cidara Therapeutics Inc
Sektor
Branche
Telefon
858-752-6170
Adresse
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Vergleichen Sie CDTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
63.25 | 1.57B | 56.54M | -30.70M | -31.05M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-03-12 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-27 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-08 | Eingeleitet | Guggenheim | Buy |
| 2024-08-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-09-22 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-04 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-07-26 | Eingeleitet | Citigroup | Buy |
| 2017-04-21 | Eingeleitet | Raymond James | Strong Buy |
| 2017-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-04-11 | Fortgesetzt | Wedbush | Outperform |
| 2017-02-22 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-22 | Hochstufung | WBB Securities | Sell → Hold |
| 2016-12-21 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-09-23 | Herabstufung | WBB Securities | Hold → Sell |
| 2015-10-09 | Hochstufung | WBB Securities | Sell → Hold |
| 2015-05-11 | Eingeleitet | Jefferies | Buy |
| 2015-05-11 | Eingeleitet | Leerink Partners | Outperform |
| 2015-05-11 | Eingeleitet | Needham | Buy |
| 2015-05-11 | Eingeleitet | Wedbush | Outperform |
| 2015-04-23 | Eingeleitet | WBB Securities | Sell |
Alle ansehen
Cidara Therapeutics Inc Aktie (CDTX) Neueste Nachrichten
Cidara Therapeutics: Promising Trials Amidst Financial Challenges - MSN
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q2 2025 Earnings Call Transcript - MSN
Cidara Therapeutics Inc. Pullback Analyzed — Is It Time to ExitMarket Entry and Exit Point Tips From Traders - beatles.ru
A Quick Look at Today's Ratings for Cidara Therapeutics(CDTX.US), With a Forecast Between $66 to $74 - 富途牛牛
Cidara (CDTX) Q2 Cash Surges 163% - AOL.com
Cidara Therapeutics 2024 Q2 Earnings Net Loss Widens by 569.5% - AInvest
Cidara Therapeutics price target raised to $74 from $54 at Needham - TipRanks
Guggenheim raises Cidara Therapeutics stock price target to $70 on FDA meeting progress - Investing.com Canada
Cidara Therapeutics Rallies On Promising Flu Drug Progress - Finimize
Cidara Therapeutics Reports Positive Trial Results and Financial Growth - TipRanks
Earnings call transcript: Sidera Therapeutics’ Q2 2025 innovation focus - Investing.com
Cidara Therapeutics: Q2 Earnings Snapshot - Manistee News Advocate
Cidara Therapeutics stock price target raised to $66 at Citizens JMP - Investing.com Australia
Cidara Therapeutics Inc (CDTX) Q2 2025 Earnings Call Highlights: Promising Clinical Trial ... - Yahoo Finance
Cidara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cidara Therapeutics 2024 Q2 Earnings Deepened Losses Amid Strong Clinical Progress - AInvest
Transcript : Cidara Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Cidara Therapeutics reports Q2 EPS ($1.65), consensus ($1.82) - TipRanks
Cidara Therapeutics Q2 net loss narrows - MarketScreener
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Spero leads infectious disease gains with 252% stock jump - BioWorld MedTech
RBC Capital raises Cidara Therapeutics stock price target to $115 on market potential - Investing.com Canada
Cidara Therapeutics price target raised to $115 from $75 at RBC Capital - TipRanks
Cidara Therapeutics Inc expected to post a loss of $2.00 a shareEarnings Preview - TradingView
Cidara Therapeutics CDTX Q2 2025 Earnings Preview Upside Potential on Analyst Optimism - AInvest
Is Cidara Therapeutics Inc. stock overvalued or undervaluedCapitalize on market momentum for maximum gains - Jammu Links News
Should I hold or sell Cidara Therapeutics Inc. stock in 2025Achieve breakthrough gains with expert advice - Jammu Links News
Cidara Therapeutics Inc. Stock Analysis and ForecastInvest smarter with data-backed insights - Jammu Links News
How strong is Cidara Therapeutics Inc. company’s balance sheetGet daily updates on promising stocks - Jammu Links News
What institutional investors are buying Cidara Therapeutics Inc. stockBuild a diversified portfolio for risk management - Jammu Links News
What makes Cidara Therapeutics Inc. stock price move sharplyRecord-breaking capital gains - Jammu Links News
Is Cidara Therapeutics Inc. a good long term investmentInvest with confidence backed by data - Jammu Links News
What are analysts’ price targets for Cidara Therapeutics Inc. in the next 12 monthsDynamic portfolio growth - Jammu Links News
What is the risk reward ratio of investing in Cidara Therapeutics Inc. stockAchieve rapid wealth accumulation through smart investing - Jammu Links News
What is the dividend policy of Cidara Therapeutics Inc. stockFree Trading Psychology Coaching - Jammu Links News
What are Cidara Therapeutics Inc. company’s key revenue driversAchieve rapid capital gains with smart investing - Jammu Links News
Will Cidara Therapeutics Inc. Bounce From 52 Week LowTriple Digit Growth Focused Trade Plan Reviewed - metal.it
Moving Average Crossover Confirms Uptrend in Cidara Therapeutics Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
How Cidara Therapeutics Inc. stock performs during market volatilityHigh Win Rate Trading Opportunities Detected - beatles.ru
Can trapped investors hope for a rebound in Cidara Therapeutics Inc.Real-Time Trade Insights Spark Market Reactions - metal.it
Will Cidara Therapeutics Inc. stock split in the near futureInvestment Strategy With Predictable Gains Outlined - metal.it
Candidemia Market Analysis and Forecast Report 2025-2035 Featuring Pfizer, Cidara Therapeutics, Scynexis, Merck, Basilea Pharmaceutica, Lupin Pharmaceuticals, Astellas PharmaResearchAndMarkets.com - FinancialContent
Why Cidara Therapeutics Inc. stock attracts strong analyst attentionBuy Signal Based on Chart Analysis Confirmed - metal.it
Why is Cidara Therapeutics Inc. stock attracting strong analyst attentionFree Market Volatility Navigation Tips - Jammu Links News
What is Cidara Therapeutics Inc. company’s growth strategySwing Trade Updates To Watch Now - jammulinksnews.com
Why Cidara Therapeutics Inc. stock attracts strong analyst attention Fundamental + Technical Combined Watchlist - metal.it
Finanzdaten der Cidara Therapeutics Inc-Aktie (CDTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):